Thu, Dec 25, 2014, 3:59 AM EST - U.S. Markets closed for Christmas


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • zake1 zake1 Jul 1, 2013 8:37 PM Flag

    lazard says this

    1:07 PM Lazard says Arikace is "still viable," which will hopefully be some consolation for Insmed (INSM -15.4%) shareholders who are taking a rather nasty hit right now courtesy of Phase 3 trial results (previous) which suggested CF patients treated with Novartis' (NVS +0.4%) Tobi performed better on lung function tests — the results were close enough however, to allow INSM to claim statistical non-inferiority. Lazard's Joshua Schimmer reiterates a Buy rating and a $24 price target. Investors are also reminded that UBS believes the drug's real potential might lie in non-tuberculous mycobacteria rather than CF. Read comments

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Insmed sell-off on Arikace data overdone, says Canaccord: Canaccord views the sell-off in shares of Insmed as overdone and keeps a Buy rating on the stock. The firm says Arikace’s activity in Cystic Fibrosis is supportive of good drug localization to deep lung and upped its price target for shares to $18 from $17

15.29+0.15(+0.99%)Dec 24 1:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.